JP7570100B2 - 老化細胞を除去する方法、および老化細胞の調製方法 - Google Patents

老化細胞を除去する方法、および老化細胞の調製方法 Download PDF

Info

Publication number
JP7570100B2
JP7570100B2 JP2020555569A JP2020555569A JP7570100B2 JP 7570100 B2 JP7570100 B2 JP 7570100B2 JP 2020555569 A JP2020555569 A JP 2020555569A JP 2020555569 A JP2020555569 A JP 2020555569A JP 7570100 B2 JP7570100 B2 JP 7570100B2
Authority
JP
Japan
Prior art keywords
cells
senescent cells
bptes
kga
senescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555569A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020095971A1 (ja
JPWO2020095971A5 (https=
Inventor
真 中西
由和 城村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of JPWO2020095971A1 publication Critical patent/JPWO2020095971A1/ja
Publication of JPWO2020095971A5 publication Critical patent/JPWO2020095971A5/ja
Application granted granted Critical
Publication of JP7570100B2 publication Critical patent/JP7570100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020555569A 2018-11-08 2019-11-07 老化細胞を除去する方法、および老化細胞の調製方法 Active JP7570100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018210300 2018-11-08
JP2018210300 2018-11-08
PCT/JP2019/043570 WO2020095971A1 (ja) 2018-11-08 2019-11-07 老化細胞を除去する方法、および老化細胞の調製方法

Publications (3)

Publication Number Publication Date
JPWO2020095971A1 JPWO2020095971A1 (ja) 2021-10-07
JPWO2020095971A5 JPWO2020095971A5 (https=) 2022-11-14
JP7570100B2 true JP7570100B2 (ja) 2024-10-21

Family

ID=70612079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555569A Active JP7570100B2 (ja) 2018-11-08 2019-11-07 老化細胞を除去する方法、および老化細胞の調製方法

Country Status (5)

Country Link
US (2) US20220119768A1 (https=)
EP (1) EP3878470A4 (https=)
JP (1) JP7570100B2 (https=)
CN (1) CN112996541B (https=)
WO (1) WO2020095971A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7016983B1 (ja) * 2021-01-21 2022-02-07 株式会社ユーグレナ Ｇｌｓ１遺伝子阻害用化粧料組成物、ｇｌｓ１遺伝子阻害剤、老化細胞除去用化粧料組成物及び老化細胞除去剤
EP4346813A4 (en) * 2021-05-26 2025-08-06 Unity Biotechnology Inc METHODS OF TREATMENT OF RETINAL VASCULOPATHIES
US20250108036A1 (en) * 2021-11-10 2025-04-03 Lifeceutix Co., Ltd. Compositions for removing senescent cells and uses thereof
CN116008519A (zh) * 2022-12-14 2023-04-25 贵州医科大学 一种新型细胞衰老检测试剂盒及其检测方法和应用
CN120752045A (zh) * 2023-02-27 2025-10-03 协和医药化工股份有限公司 细胞衰老的预防或改善剂
CN121648114A (zh) * 2026-02-06 2026-03-13 北京大学 一种小分子化合物在制备用于抗衰老的产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2141241A1 (en) * 2008-07-03 2010-01-06 Helmholtz-Zentrum für Infektionsforschung GmbH Senescence cells and methods for its production
CA2934700A1 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
US10221459B2 (en) * 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
WO2017008060A1 (en) * 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US20170348398A1 (en) * 2016-06-03 2017-12-07 Vanderbilt University Compositions and methods for decreasing blood glucagon levels

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
American Journal of Respiratory Cell and Molecular Biology，2019年04月，Vol.61, No.4，pp.492-500
DU K. et al.，Gastroenterology，2018年04月，Vol.154，p.1465-1479
HORTON MR. et al.，Targeting Glutamine Metabolism as a Novel Means of Arresting and Reversing Pulmonary Fibrosis，Am J Respir Crit Care Med，2019年05月，Vol.199:A2420，A101
JOHMURA Y. et al.，Necessary and sufficient role for a mitosis skip in senescence induction.，Molecular Cell，2014年，Vol.55，p.73-84
KAMARAJAN P. et al.，Journal of Proteome Research，2017年，Vol.16，p.1315-1326，doi: 10.1007/s10886-016-0726-7
KIM HJ. et al.，J Gerontol A Biol Sci Med Sci，2013年，Vol.68, No.10，p.1145-1156
Oncotarget，2016年，Vol.7, No.7，pp.7925-7939
TAKEUCHI H. et al.，The Journal of Biological Chemistry，2006年，Vol.281, No.30，p.21362-21368
UNTERLUGGAUER H. et al.，Premature senescence of human endothelial cells induced by inhibition of glutaminase.，Biogerontology，2008年，Vol.9，p.247-259
神経治療，2016年，Vol.33, No.3，pp.303-306
関根進，抗体医薬の現状と課題，科学技術動向，2009年，Vol.103，pp.2,13-25

Also Published As

Publication number Publication date
EP3878470A1 (en) 2021-09-15
CN112996541B (zh) 2024-08-06
JPWO2020095971A1 (ja) 2021-10-07
US20220119768A1 (en) 2022-04-21
US20260049282A1 (en) 2026-02-19
WO2020095971A1 (ja) 2020-05-14
EP3878470A4 (en) 2022-08-31
CN112996541A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
JP7570100B2 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
EP2282779B1 (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
Tang et al. KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1
Yang et al. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: role of epigenetic regulation
Zhang et al. Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases
Zou et al. C/EBPβ knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NFκB
US20150164901A1 (en) Compounds, compositions and methods for treating or preventing neurodegenerative disorders
Cheng et al. LGALS3 regulates endothelial-to-mesenchymal transition via PI3K/AKT signaling pathway in silica-induced pulmonary fibrosis
JP2018517671A (ja) 抗癌組成物及びその使用
Wen et al. Inhibition of TNFAIP1 ameliorates the oxidative stress and inflammatory injury in myocardial ischemia/reperfusion injury through modulation of Akt/GSK-3β/Nrf2 pathway
WO2019180664A1 (en) Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
JP6918839B2 (ja) 概日時計の乱れに関連するマイクロバイオームの調節異常を処置するための方法及び医薬組成物
Li et al. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation
CN114650818A (zh) 用于治疗与dux4表达相关的疾病诸如肌营养不良症和癌症的酪蛋白激酶1抑制剂
Qin et al. Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD
JP2019510061A (ja) 高脂肪食関連疾患を阻害する方法
Ding et al. Mechanism of Lung Fibrosis Caused by Rare Earth Samarium Oxide Through Hippo Signaling Pathway and the Intervention of GBE: R. Ding et al.
JP2023159469A (ja) 肥満症を予防又は治療するための医薬組成物
CN114432302A (zh) 小分子sr9009在抗衰老以及减轻衰老引起的慢性炎症中的用途
Li et al. NEK2 promotes the progression of osteoarthritis by stabilizing ATF2 through phosphorylation at Ser-112 and inhibiting autophagy
JP7849916B2 (ja) 非ヒト哺乳動物のがんの治療剤
Shu et al. The Limb-bud and Heart (LBH) promotes renal fibrosis through endoplasmic reticulum stress-induced pyroptosis and partial epithelial-mesenchymal transition in renal tubular epithelial cells
Zhou Determination the Role of Constitutive Nitric Oxide Synthase in Skin Carcinogenesis Post UV Irradiation
Zhang et al. Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the Alzheimer's disease mouse model by regulating the expression of App secretases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241001

R150 Certificate of patent or registration of utility model

Ref document number: 7570100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150